Viking Therapeutics, Inc. Share Price & Technical Analysis
VKTX · $30.80 (-0.29%)
Healthcare / Biotechnology
$30.80
-0.29%
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatoh…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-2% return in May, -8% avg return in past 3 year May month.
-8% return in 2026, 103% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -18% | 18% | -2% | -5% | -2% | – | – | – | – | – | – | – | -8% |
| 25 | -19% | -8% | -15% | 20% | -7% | -1% | 23% | -16% | -3% | 44% | -3% | -3% | 12% |
| 24 | 30% | 217% | 1% | -3% | -20% | -15% | 7% | 13% | -1% | 15% | -28% | -23% | 193% |
| 23 | -4% | 25% | 51% | 27% | 3% | -26% | -10% | -5% | -20% | -11% | 26% | 50% | 105% |
| 22 | -21% | -11% | -9% | -20% | -8% | 32% | 3% | 7% | -16% | 46% | -2% | 129% | 130% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$3.58B
P/E ratio
—
52W high
$43.15
52W low
$22.96
Volume
24,06,391
Beta
0.71
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Viking Therapeutics, Inc. share price today?
- Viking Therapeutics, Inc. (VKTX) last traded around $30.80 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does VKTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for VKTX. Download the app for real-time alerts.
- How can I analyze Viking Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.